September 2026 Biopharma Hedge Fund Stock Picks: VRDN, MAZE, and ANNX

For September 2026, our Hedge Fund Stock Picks highlight three biopharma companies with different clinical, commercial, and catalyst risks: Viridian Therapeutics (VRDN), Maze Therapeutics (MAZE), and Annexon (ANNX). Each of these is a biopharma-focused hedge fund consensus favorite, with 11 of 36 top biopharma hedge fund holders in VRDN, 9 in MAZE, and 8 in ANNX, which puts all of these above or near the top 10% of public smid-cap biopharma companies, an important validation of the quality of the company and its therapeutic assets.

Want to read more?

Subscribe to bpiq.com to keep reading this exclusive post.

Subscribe Now